Featured Research

from universities, journals, and other organizations

Researchers study alcohol addiction using optogenetics

Date:
December 16, 2013
Source:
Wake Forest Baptist Medical Center
Summary:
Researchers are gaining a better understanding of the neurochemical basis of addiction with a new technology called optogenetics.

Wake Forest Baptist Medical Center researchers are gaining a better understanding of the neurochemical basis of addiction with a new technology called optogenetics.

In neuroscience research, optogenetics is a newly developed technology that allows researchers to control the activity of specific populations of brain cells, or neurons, using light. And it's all thanks to understanding how tiny green algae, that give pond scum its distinctive color, detect and use light to grow.

The technology enables researchers like Evgeny A. Budygin, Ph.D., assistant professor of neurobiology and anatomy at Wake Forest Baptist, to address critical questions regarding the role of dopamine in alcohol drinking-related behaviors, using a rodent model.

"With this technique, we've basically taken control of specific populations of dopamine cells, using light to make them respond -- almost like flipping a light switch," said Budygin. "These data provide us with concrete direction about what kind of patterns of dopamine cell activation might be most effective to target alcohol drinking."

The latest study from Budygin and his team published online in last month's journal Frontiers in Behavioral Neuroscience. Co-author Jeffrey L. Weiner, Ph.D., professor of physiology and pharmacology at Wake Forest Baptist, said one of the biggest challenges in neuroscience has been to control the activity of brain cells in the same way that the brain actually controls them. With optogenetics, neuroscientists can turn specific neurons on or off at will, proving that those neurons actually govern specific behaviors.

"We have known for many years what areas of the brain are involved in the development of addiction and which neurotransmitters are essential for this process," Weiner said. "We need to know the causal relationship between neurochemical changes in the brain and addictive behaviors, and optogenetics is making that possible now."

The researchers used cutting-edge molecular techniques to express the light-responsive channelrhodopsin protein in a specific population of dopamine cells in the brain-reward system of rodents. They then implanted tiny optical fibers into this brain region and were able to control the activity of these dopamine cells by flashing a blue laser on them.

"You can place an electrode in the brain and apply an electrical current to mimic the way brain cells get excited, but when you do that you're activating all the cells in that area," Weiner said. "With optogenetics, we were able to selectively control a specific population of dopamine cells in a part of the brain-reward system. Using this technique, we discovered distinct patterns of dopamine cell activation that seemed to be able to disrupt the alcohol-drinking behavior of the rats."

Weiner said there is translational value from the study because "it gives us better insight into how we might want to use something like deep-brain stimulation to treat alcoholism. Doctors are starting to use deep-brain stimulation to treat everything from anxiety to depression, and while it works, there is little scientific understanding behind it, he said.

Budygin agreed. "Now we are taking the first steps in this direction," he said. "It was impossible before the optogenetic era."


Story Source:

The above story is based on materials provided by Wake Forest Baptist Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Caroline E. Bass, Valentina P. Grinevich, Dominic Gioia, Jonathan D. Day-Brown, Keith D. Bonin, Garret D. Stuber, Jeff L. Weiner, Evgeny A. Budygin. Optogenetic stimulation of VTA dopamine neurons reveals that tonic but not phasic patterns of dopamine transmission reduce ethanol self-administration. Frontiers in Behavioral Neuroscience, 2013; 7 DOI: 10.3389/fnbeh.2013.00173

Cite This Page:

Wake Forest Baptist Medical Center. "Researchers study alcohol addiction using optogenetics." ScienceDaily. ScienceDaily, 16 December 2013. <www.sciencedaily.com/releases/2013/12/131216094648.htm>.
Wake Forest Baptist Medical Center. (2013, December 16). Researchers study alcohol addiction using optogenetics. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2013/12/131216094648.htm
Wake Forest Baptist Medical Center. "Researchers study alcohol addiction using optogenetics." ScienceDaily. www.sciencedaily.com/releases/2013/12/131216094648.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins